A
14.12
0.05 (0.36%)
| Penutupan Terdahulu | 14.07 |
| Buka | 14.00 |
| Jumlah Dagangan | 611,350 |
| Purata Dagangan (3B) | 1,516,440 |
| Modal Pasaran | 1,550,652,288 |
| Harga / Jualan (P/S) | 0.660 |
| Harga / Buku (P/B) | 4.94 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | 16,317.06% |
| EPS Cair (TTM) | -3.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -99.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.69% |
| Nisbah Semasa (MRQ) | 12.05 |
| Aliran Tunai Operasi (OCF TTM) | -206.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -182.62 M |
| Pulangan Atas Aset (ROA TTM) | -40.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -83.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Amylyx Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 9.54% |
| % Dimiliki oleh Institusi | 85.89% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 34.00 (HC Wainwright & Co., 140.79%) | Beli |
| Median | 21.00 (48.73%) | |
| Rendah | 19.00 (B of A Securities, 34.56%) | Beli |
| Purata | 24.67 (74.72%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 14.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (140.79%) | Beli | 15.05 |
| 10 Feb 2026 | 28.00 (98.30%) | Beli | 14.89 | |
| Stifel | 03 Mar 2026 | 21.00 (48.73%) | Beli | 14.11 |
| B of A Securities | 20 Feb 2026 | 19.00 (34.56%) | Beli | 14.01 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BEDROSIAN CAMILLE L | 14.10 | 15.30 | 89,529 | 1,254,606 |
| COHEN JOSHUA B | 14.10 | 15.30 | 219,583 | 3,060,982 |
| FRATES JAMES M | 14.10 | 15.30 | 88,081 | 1,232,451 |
| KLEE JUSTIN B. | 14.10 | 15.30 | 219,583 | 3,060,982 |
| MAZZARIELLO GINA | 14.10 | 15.30 | 67,816 | 947,993 |
| Jumlah Keseluruhan Kuantiti Bersih | 684,592 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 9,557,014 | |||
| Purata Pembelian Keseluruhan ($) | 14.10 | |||
| Purata Jualan Keseluruhan ($) | 15.30 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BEDROSIAN CAMILLE L | Pegawai | 05 Mar 2026 | Diperolehi (+) | 95,990 | 14.10 | 1,353,459 |
| KLEE JUSTIN B. | Pegawai | 05 Mar 2026 | Diperolehi (+) | 248,865 | 14.10 | 3,508,997 |
| COHEN JOSHUA B | Pegawai | 05 Mar 2026 | Diperolehi (+) | 248,865 | 14.10 | 3,508,997 |
| MAZZARIELLO GINA | Pegawai | 05 Mar 2026 | Diperolehi (+) | 74,660 | 14.10 | 1,052,706 |
| FRATES JAMES M | Pegawai | 05 Mar 2026 | Diperolehi (+) | 95,990 | 14.10 | 1,353,459 |
| MAZZARIELLO GINA | Pegawai | 02 Mar 2026 | Jual (-) | 6,844 | 15.30 | 104,713 |
| BEDROSIAN CAMILLE L | Pegawai | 02 Mar 2026 | Jual (-) | 6,461 | 15.30 | 98,853 |
| FRATES JAMES M | Pegawai | 02 Mar 2026 | Jual (-) | 7,909 | 15.30 | 121,008 |
| COHEN JOSHUA B | Pegawai | 02 Mar 2026 | Jual (-) | 29,282 | 15.30 | 448,015 |
| KLEE JUSTIN B. | Pegawai | 02 Mar 2026 | Jual (-) | 29,282 | 15.30 | 448,015 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |